RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oxford Biomedica Stock

Oxford Biomedica ROCE 2024

Oxford Biomedica ROCE

-1.16

Ticker

OXB.L

ISIN

GB00BDFBVT43

WKN

A2JLRX

In 2024, Oxford Biomedica's return on capital employed (ROCE) was -1.16, a 361.17% increase from the -0.25 ROCE in the previous year.

Oxford Biomedica Aktienanalyse

What does Oxford Biomedica do?

Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Oxford Biomedica's Return on Capital Employed (ROCE)

Oxford Biomedica's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Oxford Biomedica's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Oxford Biomedica's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Oxford Biomedica’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Oxford Biomedica stock

What is the ROCE (Return on Capital Employed) of Oxford Biomedica this year?

The ROCE of Oxford Biomedica is -1.16 undefined this year.

How has the ROCE (Return on Capital Employed) of Oxford Biomedica developed compared to the previous year?

The ROCE of Oxford Biomedica has increased by 361.17% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Oxford Biomedica?

A high Return on Capital Employed (ROCE) indicates that Oxford Biomedica has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Oxford Biomedica?

A low ROCE (Return on Capital Employed) can indicate that Oxford Biomedica has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Oxford Biomedica impact the company?

An increase in the ROCE of Oxford Biomedica can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Oxford Biomedica affect the company?

A decrease in ROCE of Oxford Biomedica can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Oxford Biomedica?

Some factors that can affect Oxford Biomedica's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Oxford Biomedica so important for investors?

The ROCE of Oxford Biomedica is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Oxford Biomedica take to improve the ROCE?

To improve the ROCE, Oxford Biomedica can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Oxford Biomedica pay?

Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.

What is the dividend yield of Oxford Biomedica?

The current dividend yield of Oxford Biomedica is .

When does Oxford Biomedica pay dividends?

Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oxford Biomedica?

Oxford Biomedica paid dividends every year for the past 0 years.

What is the dividend of Oxford Biomedica?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oxford Biomedica located?

Oxford Biomedica is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oxford Biomedica from 10/3/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Oxford Biomedica pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Oxford Biomedica in the year 2023?

In the year 2023, Oxford Biomedica distributed 0 GBP as dividends.

In which currency does Oxford Biomedica pay out the dividend?

The dividends of Oxford Biomedica are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Oxford Biomedica stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Oxford Biomedica

Our stock analysis for Oxford Biomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxford Biomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.